Personal information

No personal information available

Activities

Works (50 of 56)

Items per page:
Page 1 of 2

Data from Ipatasertib plus Paclitaxel for Patients with <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i>-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

2024-10-01 | Preprint
Contributors: Rebecca A. Dent; Sung-Bae Kim; Mafalda Oliveira; Carlos Barrios; Joyce O’Shaughnessy; Steven J. Isakoff; Shigehira Saji; Ruffo Freitas-Junior; Manuel Philco; Igor Bondarenko et al.
Source: check_circle
Crossref

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Clinical Cancer Research
2024-10-01 | Journal article
Contributors: Rebecca A. Dent; Sung-Bae Kim; Mafalda Oliveira; Carlos Barrios; Joyce O’Shaughnessy; Steven J. Isakoff; Shigehira Saji; Ruffo Freitas-Junior; Manuel Philco; Igor Bondarenko et al.
Source: check_circle
Crossref

Supplementary Data1 from Ipatasertib plus Paclitaxel for Patients with <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i>-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

2024-10-01 | Preprint
Contributors: Rebecca A. Dent; Sung-Bae Kim; Mafalda Oliveira; Carlos Barrios; Joyce O’Shaughnessy; Steven J. Isakoff; Shigehira Saji; Ruffo Freitas-Junior; Manuel Philco; Igor Bondarenko et al.
Source: check_circle
Crossref

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Journal of Clinical Oncology
2024-06-20 | Journal article
Contributors: Miguel Martín; Elgene Lim; Mariana Chavez-MacGregor; Aditya Bardia; Jiong Wu; Qingyuan Zhang; Zbigniew Nowecki; Felipe Melo Cruz; Rustem Safin; Sung-Bae Kim et al.
Source: check_circle
Crossref

Data from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

2024-02-16 | Preprint
Contributors: Peter Schmid; Nicholas C. Turner; Carlos H. Barrios; Steven J. Isakoff; Sung-Bae Kim; Marie-Paule Sablin; Shigehira Saji; Peter Savas; Gregory A. Vidal; Mafalda Oliveira et al.
Source: check_circle
Crossref

Data from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

2024-02-16 | Preprint
Contributors: Peter Schmid; Nicholas C. Turner; Carlos H. Barrios; Steven J. Isakoff; Sung-Bae Kim; Marie-Paule Sablin; Shigehira Saji; Peter Savas; Gregory A. Vidal; Mafalda Oliveira et al.
Source: check_circle
Crossref

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Clinical Cancer Research
2024-02-16 | Journal article
Contributors: Peter Schmid; Nicholas C. Turner; Carlos H. Barrios; Steven J. Isakoff; Sung-Bae Kim; Marie-Paule Sablin; Shigehira Saji; Peter Savas; Gregory A. Vidal; Mafalda Oliveira et al.
Source: check_circle
Crossref

Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

2024-02-16 | Preprint
Contributors: Peter Schmid; Nicholas C. Turner; Carlos H. Barrios; Steven J. Isakoff; Sung-Bae Kim; Marie-Paule Sablin; Shigehira Saji; Peter Savas; Gregory A. Vidal; Mafalda Oliveira et al.
Source: check_circle
Crossref

Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

2024-02-16 | Preprint
Contributors: Peter Schmid; Nicholas C. Turner; Carlos H. Barrios; Steven J. Isakoff; Sung-Bae Kim; Marie-Paule Sablin; Shigehira Saji; Peter Savas; Gregory A. Vidal; Mafalda Oliveira et al.
Source: check_circle
Crossref

A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Clinical Cancer Research
2024-01-17 | Journal article
Contributors: David W. Cescon; John Hilton; Serafin Morales Murilo; Rachel M. Layman; Timothy Pluard; Belinda Yeo; In Hae Park; Louise Provencher; Sung-Bae Kim; Young-Hyuck Im et al.
Source: check_circle
Crossref

Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

2024-01-17 | Preprint
Contributors: David W. Cescon; John Hilton; Serafin Morales Murilo; Rachel M. Layman; Timothy Pluard; Belinda Yeo; In Hae Park; Louise Provencher; Sung-Bae Kim; Young-Hyuck Im et al.
Source: check_circle
Crossref

Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

2024-01-17 | Preprint
Contributors: David W. Cescon; John Hilton; Serafin Morales Murilo; Rachel M. Layman; Timothy Pluard; Belinda Yeo; In Hae Park; Louise Provencher; Sung-Bae Kim; Young-Hyuck Im et al.
Source: check_circle
Crossref

Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

2024-01-17 | Preprint
Contributors: David W. Cescon; John Hilton; Serafin Morales Murilo; Rachel M. Layman; Timothy Pluard; Belinda Yeo; In Hae Park; Louise Provencher; Sung-Bae Kim; Young-Hyuck Im et al.
Source: check_circle
Crossref

Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

2024-01-17 | Preprint
Contributors: David W. Cescon; John Hilton; Serafin Morales Murilo; Rachel M. Layman; Timothy Pluard; Belinda Yeo; In Hae Park; Louise Provencher; Sung-Bae Kim; Young-Hyuck Im et al.
Source: check_circle
Crossref

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

Clinical Cancer Research
2023-11-14 | Journal article
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Data from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Data from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Figure S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Supplementary Material 1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Supplementary Material 1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S1 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S2 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S3 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Table S4 from A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

2023-11-14 | Preprint
Contributors: Glenn J. Hanna; Myung-Ju Ahn; Jameel Muzaffar; Bhumsuk Keam; Daniel W. Bowles; Deborah J. Wong; Alan L. Ho; Sung-Bae Kim; Francis Worden; Tak Yun et al.
Source: check_circle
Crossref

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

Drug Safety
2023-10 | Journal article
Contributors: Joanne Wing Yan Chiu; Soo Chin Lee; James Chung-man Ho; Yeon Hee Park; Ta-Chung Chao; Sung-Bae Kim; Elgene Lim; Ching-Hung Lin; Sherene Loi; Su Ying Low et al.
Source: check_circle
Crossref

Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

2023-03-31 | Preprint
Contributors: Sherko Kuemmel; Mario Campone; Delphine Loirat; Rafael Lopez Lopez; J. Thaddeus Beck; Michelino De Laurentiis; Seock-Ah Im; Sung-Bae Kim; Ava Kwong; Guenther G. Steger et al.
Source: check_circle
Crossref

Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

2023-03-31 | Preprint
Contributors: Sherko Kuemmel; Mario Campone; Delphine Loirat; Rafael Lopez Lopez; J. Thaddeus Beck; Michelino De Laurentiis; Seock-Ah Im; Sung-Bae Kim; Ava Kwong; Guenther G. Steger et al.
Source: check_circle
Crossref

Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

2023-03-31 | Preprint
Contributors: Sherko Kuemmel; Mario Campone; Delphine Loirat; Rafael Lopez Lopez; J. Thaddeus Beck; Michelino De Laurentiis; Seock-Ah Im; Sung-Bae Kim; Ava Kwong; Guenther G. Steger et al.
Source: check_circle
Crossref

Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

2023-03-31 | Preprint
Contributors: Sherko Kuemmel; Mario Campone; Delphine Loirat; Rafael Lopez Lopez; J. Thaddeus Beck; Michelino De Laurentiis; Seock-Ah Im; Sung-Bae Kim; Ava Kwong; Guenther G. Steger et al.
Source: check_circle
Crossref

Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy

European Journal of Cancer
2023-02 | Journal article
Contributors: Sora Kang; Sung-Bae Kim
Source: check_circle
Crossref

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy

Therapeutic Advances in Medical Oncology
2023-01 | Journal article
Contributors: Hyehyun Jeong; Sung-Bae Kim
Source: check_circle
Crossref

CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience

Journal of Breast Cancer
2022 | Journal article
Contributors: Yoon Jung Jang; Jae Ho Jeong; Jeong Eun Kim; Jin-Hee Ahn; Kyung Hae Jung; Sung-Bae Kim
Source: check_circle
Crossref

Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories

Journal of Breast Cancer
2022 | Journal article
Contributors: Suthinee Ithimakin; Napa Parinyanitikul; Sung-Bae Kim; Yoon-Sim Yap; Janice Tsang; Inda S Soong; Yukinori Ozaki; Shinji Ohno; Makiko Ono; Jack Junjie Chan et al.
Source: check_circle
Crossref

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy

The Breast
2022-12 | Journal article
Contributors: Jae Ho Jeong; Sung-Bae Kim
Source: check_circle
Crossref

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Cancer Discovery
2022-10-18 | Journal article
Contributors: Guy Jerusalem; Yeon Hee Park; Sara A. Hurvitz; Shanu Modi; Fabrice Andre; Ian E. Krop; Xavier Gonzalez-Farre; Benoit You; Cristina Saura; Sung-Bae Kim et al.
Source: check_circle
Crossref

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Journal of Clinical Oncology
2022-09-10 | Journal article
Contributors: Lin Shen; Ken Kato; Sung-Bae Kim; Jaffer A. Ajani; Kuaile Zhao; Zhiyong He; Xinmin Yu; Yongqian Shu; Qi Luo; Jufeng Wang et al.
Source: check_circle
Crossref

RNA Sequencing for Elucidating an Intronic Variant of Uncertain Significance (SDHD c.314+3A>T) in Splicing Site Consensus Sequences

Annals of Laboratory Medicine
2022-05-01 | Journal article
Contributors: Hyunjung Gu; Jinyoung Hong; Woochang Lee; Sung-Bae Kim; Sail Chun; Won-Ki Min
Source: check_circle
Crossref

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Clinical Cancer Research
2022-01-01 | Journal article
Contributors: Sherko Kuemmel; Mario Campone; Delphine Loirat; Rafael Lopez Lopez; J. Thaddeus Beck; Michelino De Laurentiis; Seock-Ah Im; Sung-Bae Kim; Ava Kwong; Guenther G. Steger et al.
Source: check_circle
Crossref

Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Journal of Breast Cancer
2021 | Journal article
Contributors: Jee Hyun Kim; Seock-Ah Im; Sung Hoon Sim; Eustratios Bananis; Xin Huang; Hyun Seon Kim; Sung-Bae Kim
Source: check_circle
Crossref
Items per page:
Page 1 of 2

Peer review (9 reviews for 5 publications/grants)

Review activity for Breast cancer research and treatment. (3)
Review activity for European journal of cancer. (1)
Review activity for The Breast. (3)
Review activity for The lancet oncology. (1)
Review activity for The Lancet regional health. (1)